Continued Use of Zonisamide Following Development of Renal Calculi
Abstract
The reported incidence of renal calculi complicating Zonisamide (ZNS) therapy for epilepsy ranges from 0.2 to 4.4%(exp 1-3) Typically this complication leads to discontinuation of the drug. For patients uniquely responsive to Zonisamide, the benefits of continued treatment may outweigh the risk of calculus recurrence. We report three patients who developed nephrolithiasis but continued ZNS treatment without recurrence of calculi.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 15, 2004
- Accession Number
- ADA425098
Entities
People
- Amit Verma
- Karen C. Richards
- Michael C. Smith
Organizations
- Baylor College of Medicine